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1. INTRODUCTION {#ccr32656-sec-0001}
===============

A 73‐year‐old woman with a long‐standing history of untreated chronic lymphocytic leukemia (CLL) presented with fatigue and progressive anemia. A bone marrow biopsy was performed for suspicion of disease progression and exclusion of alternative conditions.

Her peripheral blood showed atypical lymphocytes with dimorphic cytologic features (Figure [1](#ccr32656-fig-0001){ref-type="fig"}, panels A‐B) including a subset of intermediate‐sized cells with expanded cytoplasm (arrows). Her bone marrow was involved by nodular aggregates (Figure [1](#ccr32656-fig-0001){ref-type="fig"}, panel C) of composite lymphoma consisting of two morphologically and immunophenotypically distinct populations of abnormal B lymphocytes: small mature cells (Figure [1](#ccr32656-fig-0001){ref-type="fig"}, panel D, lower right) consistent with her known CLL and a surrounding population of larger cells with more open chromatin and distinct nucleoli (Figure [1](#ccr32656-fig-0001){ref-type="fig"}, panel D, upper left) and antigen expression most suggestive of marginal zone or lymphoplasmacytic lymphoma.

![Peripheral blood film (A‐B, 60× objective) with dimorphic atypical lymphocytes and bone marrow biopsy (C, 10× objective; D, 100× objective) with nodular lymphoid infiltrates accounting for the majority of marrow cellularity. Two distinct B‐cell populations differentially express CD5, CD20, CD79, and sIg by immunohistochemistry (E‐F, 4× objective; G, 10× objective; H, 100× objective) and/or flow cytometry (I‐L, magenta: CLL; blue: second primary non‐Hodgkin lymphoma)](CCR3-8-396-g001){#ccr32656-fig-0001}

The risk of developing a second primary malignancy is more than twice as high in patients with CLL than those without and must be considered in the setting of emerging cytopenias.[1](#ccr32656-bib-0001){ref-type="ref"} Among secondary hematologic malignancies, most of this excess risk is due to additional non‐Hodgkin lymphomas.[2](#ccr32656-bib-0002){ref-type="ref"} In this case, the patient\'s worsening anemia was attributed to the combination of her new secondary non‐Hodgkin lymphoma in composite with her known CLL.
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